Effect of somatostatin analogue (SMS 201-995, sandostatin) on pancreatic secretion in humans

Creutzfeldt, W.; Lembcke, B.; Fölsch, Ulrich R.; Schleser, S; Koop, Irmtraut

doi:10.1016/0002-9343(87)90426-8

Cited by 83 publications

(34 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is clear that pancreatic enzyme supplement by itself offers no improvement in cases of steatorrhea. Decreases in pancreatic lipase output of 1/3 to 1/4 observed in this study do not differ from those previously reported (10).…”

Section: Discussionsupporting

confidence: 57%

“…Accordingly, a method for administering less than 100 jug may be worth considering in order to reduce steatorrhea. Also, as pointed out by Creutzfeldt et al (10), steatorrhea due to the analogue administration may not persist for a long time. It seems that due attention should be paid to minor adverse reactions such as steatorrhea in the beginning of analogue administration.…”

Section: Discussionmentioning

confidence: 92%

See 1 more Smart Citation

Octreotide Decreases Biliary and Pancreatic Exocrine Function, and Induces Steatorrhea in Healthy Subjects.

et al. 1994

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 57%

Section: Discussionmentioning

confidence: 92%

Octreotide Decreases Biliary and Pancreatic Exocrine Function, and Induces Steatorrhea in Healthy Subjects.

et al. 1994

View full text Add to dashboard Cite

“…This adaptation to the inhibitory effects of octreotide has been well documented in studies in normal subjects. 75,76 After seven days of treatment with octreotide (100 to 300 mg per day), the initial inhibitory effects on the secretion of gastric acid, amylase, trypsin, and lipase diminish or disappear. Nevertheless, short-term therapy with octreotide is beneficial in patients undergoing elective pancreatic surgery and in those with variceal bleeding, intestinal fistulas, or secretory diarrhea (Table 2).…”

Section: Discussionmentioning

confidence: 99%

Octreotide

et al. 1996

View full text Add to dashboard Cite

“…Moreover, it has been repeatedly shown that octreotide administered either intravenously or subcutaneously could blunt the postprandial increase in splanchnic blood flow. 14,15,[19][20][21] The vasoconstrictive effect of octreotide on the splanchnic circulation is thought to be mediated partly by an inhibition of glucagon secretion 22 ; a direct effect on the smooth muscle vasculature has also been suggested. 23 We did not find any decrease in fasted glucagon plasma levels after octreotide infusion.…”

Section: Discussionmentioning

confidence: 99%

Octreotide in Hepatorenal Syndrome: A Randomized, Double–Blind, Placebo–Controlled, Crossover Study

Pomier‐Layrargues

2003

Hepatology

137

View full text Add to dashboard Cite

The hepatorenal syndrome (HRS) is related to vasoconstriction of the renal cortex induced by systemic hypovolemia that follows splanchnic vasodilatation as the primary event in the cascade of hemodynamic changes associated with portal hypertension. We evaluated the effects of octreotide, a splanchnic vasoconstrictor, on HRS in cirrhotic patients. We compared the effects of octreotide infusion (50 g/h) to placebo using a randomized, doubleblind, cross-over design over 2, 4-day periods. Nineteen patients were included, and 14 patients could complete the 2 phases of the study (group 1: placebo first; n ‫؍‬ 8 and group 2: octreotide first; n ‫؍‬ 6) The end point of the study was to evaluate improvement in renal function as defined by a 20% decrease in serum creatinine value after a 4-day treatment as compared with baseline. In all the patients, a normal central venous pressure was maintained by daily intravenous administration of 2 units of albumin. The 2 groups were similar with regard to demographic data and liver and kidney function parameters at baseline. Improvement in renal function was observed in 2 patients after the placebo and 1 patient after octreotide infusion in group 1 and in 2 patients after octreotide infusion and 1 patient after placebo in group 2 (P ‫؍‬ not significant). In addition, treatment with octreotide infusion did not result in significant changes in creatinine clearance, daily urinary sodium, plasma renin activity, plasma aldosterone and glucagon levels, or renal and mesenteric artery resistance indices as measured by Doppler ultrasonography. In conclusion, the present study demonstrates that, under our experimental conditions, octreotide infusion combined with albumin is not effective for the treatment of HRS in cirrhotic patients. (HEPATOLOGY 2003;38:238-243.) T he hepatorenal syndrome (HRS) is a functional renal disorder associated with severe acute or chronic liver failure. It is always potentially reversible because no anatomic damage can be demonstrated in the kidney. This syndrome carries a very bad prognosis because it is always the consequence of severe liver insufficiency, the only definitive treatment being liver transplantation. 1 The pathophysiology of renal failure is thought to be mediated primarily by splanchnic vasodilatation leading to systemic hypovolemia; a cascade of vasoactive mechanisms is then initiated including compensatory activation of vasoconstrictor catecholamines, renin, aldosterone, antidiuretic hormone, and endothelin; a marked vasoconstriction of the renal cortex ensues, glomerular filtration decreases, and the kidney function deteriorates. 2 Over recent years, several attempts have been made to correct the cortical renal vasoconstriction by using splanchnic vasoconstrictors, in the hope of reversing splanchnic vasodilatation, which is thought to be the primary pathogenetic event. The efficacy of ornipressin, 3-5 terlipressin, 6-10 and octreotide alone 11 or combined with midodrine 12 has been tested in small uncontrolled pilot trials. Terlipressin appe...

show abstract

Effect of somatostatin analogue (SMS 201-995, sandostatin) on pancreatic secretion in humans

Cited by 83 publications

References 16 publications

Octreotide Decreases Biliary and Pancreatic Exocrine Function, and Induces Steatorrhea in Healthy Subjects.

Octreotide Decreases Biliary and Pancreatic Exocrine Function, and Induces Steatorrhea in Healthy Subjects.

Octreotide

Octreotide in Hepatorenal Syndrome: A Randomized, Double–Blind, Placebo–Controlled, Crossover Study

Contact Info

Product

Resources

About